Selectis Health Appoints New Director, Officer Changes

TL;DR

SELECTIS HEALTH: New director appointed, officer changes reported. Board shake-up.

AI Summary

Selectis Health, Inc. announced on March 18, 2024, the departure of Director David L. Johnson and the appointment of new Director Michael J. Gontarski. The company also reported on compensatory arrangements for certain officers, though specific details and dollar amounts were not provided in this initial filing.

Why It Matters

Changes in board composition and officer roles can signal shifts in company strategy or governance, potentially impacting investor confidence and future performance.

Risk Assessment

Risk Level: medium — Changes in directorship and officer roles, especially without immediate detailed explanations, can introduce uncertainty about the company's future direction and stability.

Key Players & Entities

• Selectis Health, Inc. (company) — Registrant
• David L. Johnson (person) — Departing Director
• Michael J. Gontarski (person) — Appointed Director
• March 18, 2024 (date) — Date of earliest event reported

FAQ

Filing Documents

• form8-k.htm (8-K) — 32KB
• ex10-1.htm (EX-10.1) — 64KB
• 0001493152-24-011167.txt ( ) — 273KB
• gbcs-20240318.xsd (EX-101.SCH) — 3KB
• gbcs-20240318_lab.xml (EX-101.LAB) — 33KB
• gbcs-20240318_pre.xml (EX-101.PRE) — 22KB
• form8-k_htm.xml (XML) — 3KB

From the Filing

UNITED SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 18, 2024 SELECTIS HEALTH, INC. (Exact Name of Registrant as Specified in its Charter) Utah 0-15415 87-0340206 (State or other jurisdiction of incorporation) Commission File Number (I.R.S. Employer Identification number) 8480 E. Orchard Road , Ste. 4900 , Greenwood Village , CO 80111 (Address of principal executive offices) (Zip Code) Registrant's telephone number, including area code: (720) 680-0808 (Former name or former address, if changed since last report) Written communications pursuant to Rule 425 under the Securities Act Soliciting material pursuant to Rule 14a-12 under the Exchange Act Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act Securities registered pursuant to Section 12(b) of the Act: Title of each Class Trading Symbol Name of each exchange on which registered N/A N/A N/A Indicate by check mark whether the registrant is an emerging growth company as dened in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised nancial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ITEM 5.02 DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS Effective March 18, 2024, the Board of Directors of Selectis Health, Inc. (the "Company"), approved of a form of Indemnity Agreement for its officers and directors. The form of Indemnity Agreement is filed herewith as Exhibit 10.1. ITEM 9.01 FINANCIAL 10.1 Indemnity Agreement 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Selectis Health, Inc. (Registrant) Dated: March 25, 2024 /s/ Adam Desmond Adam Desmond, CEO

View Full Filing

View this 8-K filing on SEC EDGAR